港股异动 | 维升药业-B(02561)涨超4% 帕罗培特立帕肽近期在博鳌完成首例处方

智通财经
Nov 03, 2025

智通财经APP获悉,维升药业-B(02561)涨超4%,截至发稿,涨4.68%,报39.8港元。

消息面上,近期,帕罗培特立帕肽(Palopegteriparatide,TransCon PTH)在上海交通大学医学院附属瑞金医院海南医院(海南博鳌研究型医院)开具首例处方。据悉,该药目前已在欧美主要国家获批上市,是全球首个且唯一一款甲旁减激素替代治疗药物。维升药业首席执行官兼执行董事卢安邦表示,帕罗培特立帕肽在博鳌完成首例处方,是维升药业致力于内分泌领域创新的重要一步。这款突破性治疗药物有望帮助患者摆脱传统治疗的困境。公司将继续与各方紧密合作,加速推动该药国内全面获批,并持续深耕内分泌创新疗法。

据招股书,公司研发进展最快的是隆培促生长素(长效生长激素),公司预计在2025下半年国内获批上市,有望成为国内第三款上市的长效生长激素。目前,公司拥有2款独特品种,分别为那韦培肽和帕罗培特立帕肽,后者有望在2025年底递交上市申请,据悉,今年6月,维升药业与药明生物达成合作,推进本地化生产,努力以价优高值的产品满足国内患者临床需求。今年7月,维升又与安科生物达成合作,共同推进产品的商业化,未来市场前景值得期待。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10